| Followers | 843 |
| Posts | 122925 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Thursday, June 03, 2021 12:14:49 PM
OGN spin-off from MRK begins trading today:
https://www.businesswire.com/news/home/20210602006079/en
https://www.businesswire.com/news/home/20210602006079/en
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent OGN News
- La Commissione Europea (CE) approva POHERDY® (pertuzumab), messo a punto da Henlius e Organon, il primo biosimilare di PERJETA (pertuzumab) approvato in Europa • Business Wire • 04/30/2026 05:30:00 PM
- Europäische Kommission erteilt Marktzulassung für POHERDY® (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab) • Business Wire • 04/30/2026 05:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:59:06 PM
- La Commission européenne (CE) approuve le POHERDY® (pertuzumab) de Henlius et Organon, premier médicament biosimilaire du PERJETA (pertuzumab) autorisé en Europe • Business Wire • 04/30/2026 03:17:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 12:16:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 11:50:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 11:48:45 AM
- Organon Reports Results for the First Quarter Ended March 31, 2026 • Business Wire • 04/30/2026 11:30:00 AM
- European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe • PR Newswire (US) • 04/29/2026 02:00:00 PM
- Organon Cancels First Quarter Earnings Call • Business Wire • 04/29/2026 11:30:00 AM
- European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe • Business Wire • 04/29/2026 09:30:00 AM
- Sun Pharma signe un accord définitif pour acquérir Organon • Business Wire • 04/28/2026 12:58:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 09:18:27 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 09:17:42 PM
- サンファーマ、オルガノン買収に関する正式契約を締結 • Business Wire • 04/27/2026 08:49:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 07:58:02 PM
- Sun Pharma unterzeichnet endgültige Vereinbarung zur Übernahme von Organon • Business Wire • 04/27/2026 10:36:00 AM
- Organon Jumps 15% as Sun Pharma Agrees $11.8bn Buyout • IH Market News • 04/27/2026 10:11:06 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 10:09:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/27/2026 10:06:01 AM
- Sun Pharma signs Definitive Agreement to Acquire Organon • Business Wire • 04/26/2026 11:51:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:35:03 PM
- Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 • Business Wire • 04/16/2026 11:30:00 AM
- Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis • Business Wire • 04/15/2026 11:30:00 AM
